No Data
No Data
HK stocks change | Cansinobio (06185) rose more than 6% in intraday trading, and the company stated that preliminary screening work such as monkeypox vaccine antigen has been completed.
Shares of cansinobio (06185) rose more than 6% in intraday trading. As of press time, they were up 4.15%, trading at HKD 20.6 per share, with a trading volume of HKD 16.9752 million.
CansinoBio (06185) has been removed from the Hang Seng Composite SmallCap Index.
On August 16th, the Hang Seng Index Company announced the latest quarterly results, in which Cansinobio (06185) was removed from the Hang Seng Composite SmallCap Index. The change will be implemented after the market closes on September 6th, 2024 (Friday) and will take effect from September 9th, 2024 (Monday).
Cansino Biologics Inc. (688185.SH): in regards to the development of smallpox vaccines, the company has completed preliminary work such as antigen screening.
On August 16th, Gelunhui reported that Cansino Biologics Inc. (688185.SH) has completed preliminary work such as antigen screening for the development of monkeypox vaccines. The current technology platform has the potential and capability of rapid development and preparation of monkeypox vaccines. The company will continue to monitor the progress of monkeypox outbreaks and carry out related work according to the development plan, funds, and future market space.
Cansinobio (06185.HK) plans to hold a board of directors meeting on August 29 to approve its interim performance.
Cansinobio (06185.HK) announced that the board of directors will hold a meeting on Thursday, August 29, 2024 to consider and approve the mid-term performance of the company and its subsidiaries for the six months ending on June 30, 2024, as well as propose an interim dividend (if any).
CANSINOBIO: NOTICE OF BOARD MEETING
CanSino Biologics Inc. (HKG:6185) Insiders Have Had a Fantastic Week as Stock Increased 10%, and They Haven't Stopped Buying
No Data